

# INDEX

- Acceptable daily intake (ADI), explanation of, 61, 82–84, 88, 89, 113, 114
- Activity spectrum, 5, 64  
 definitions  
 broad, 5  
 medium, 5  
 narrow, 5  
 table, 6
- Acute reference dose (ARfD), definition of, 113
- Ambient mass spectrometry, 214–216
- Amikacin, 9, 67  
 analysis, 188  
 chemical structure, 10
- Aminocyclitol, 67–69  
 chemical structure, 13
- Aminoglycosides  
 activity, 6, 7  
 analysis, 128, 132, 145, 172, 188, 192, 193, 196, 197, 202, 217, 246–249. *See also individual compounds*  
 chemical structures, 10–12, 247  
 mode of action, 9  
 MRLs, 9, 10, 87, 246  
 pharmacokinetics, 63, 67–69  
 $pK_a$ , 10–12  
 toxicity, 9  
 tolerances, 89
- Amoxicillin, 14, 69–71  
 analysis, 158, 159, 162, 163, 173, 188, 189, 193, 194  
 chemical structure, 15  
 MRLs, 85  
 tolerances, 89
- Ampicillin, 14, 69, 71  
 analysis, 142, 158, 159, 162, 163, 173, 188, 189, 193, 194, 217  
 chemical structure, 15  
 MRLs, 85, 230
- stability, 126, 131  
 tolerances, 89
- Animal Medicinal Drug Use Clarification Act (AMDUCA), 52, 95
- Antibiotic, definition of, 3
- Antimicrobial agent, definition of, 3
- AOAC Performance Tested Method (PTM) program, 154
- Apramycin, 67, 69  
 analysis, 188, 192, 198  
 chemical structure, 10  
 MRLs, 87
- Arrhenius equation, 3
- As low as reasonable achievable (ALARA), 114
- Atmospheric-pressure chemical ionization (APCI), 196, 201, 202, 205, 214, 216, 220, 234, 235, 250, 253
- Atmospheric-pressure photoionization (APPI), 192, 196, 201, 202, 220
- Automated sample preparation, 125, 126
- Avoparcin, 35, 52, 75, 95  
 chemical structure, 39
- Azithromycin, 21, 26, 72  
 chemical structure, 22
- Azodicarbonamide (ADC), 237–239
- Bacitracin, 3, 7, 35–36, 52, 75, 95  
 analysis, 180, 190  
 chemical structure, 37  
 MRLs, 88  
 stability, 132
- Bactericidal, 5–7, 9, 10, 20, 21, 27, 30, 35, 44, 45, 49, 64, 79, 154, 171
- Bacteriostatic, 5–7, 20, 21, 27, 30, 44, 45, 49, 64, 154
- Benzympenicillin (Penicillin G), 1, 7, 9, 13, 69, 70, 97–100, 126, 131, 153
- analysis, 142, 155, 158–160, 163, 188, 189, 193, 194, 296  
 chemical structure, 15  
 MRLs, 14, 82, 85  
 stability, 13, 131  
 tolerances, 89
- $\beta$ -Lactams, 8–10, 14, 64, 66, 69, 83, 102, 103, 230, 231. *See also Cephalosporins, Penicillins*  
 activity, 6, 7  
 analysis, 98, 128, 129, 131–134, 145, 156, 157, 161, 163, 164, 169–174, 176, 180, 188, 189, 193, 194, 200, 217. *See also individual compounds*  
 chemical structures, 15–18, 231  
 mode of action, 13  
 MRLs, 14, 85, 230  
 pharmacokinetics, 69–71  
 $pK_a$ , 15–18  
 stability, 69, 232  
 degradation in storage, 126
- Bioequivalence, 61, 100, 101
- Biophase, 5, 53, 65, 66, 73
- Biosensor, 165, 174–177, 245
- Biurea, 238, 239
- Bottom-up, 287, 297, 302
- Bridging study, 270
- Carbadox, 17–19, 52, 95, 227–229  
 analysis, 229–230, 248  
 chemical structure, 19, 228
- Carbenicillin, 14  
 chemical structure, 15
- Carbomycin, 72  
 chemical structure, 22
- Carnidazole  
 analysis, 240–241, 248  
 chemical structure, 240

- Cefacetril(e)  
analysis, 158  
chemical structure, 17  
MRLs, 85
- Cefalexin (cephalexin), 14  
analysis, 138, 158, 159, 173, 188  
chemical structure, 18  
MRLs, 85
- Cefalonium  
analysis, 158  
chemical structure, 17  
MRLs, 85
- Cefaprin (cephapirin)  
analysis, 138, 159, 162, 173, 174, 188, 194  
chemical structure, 17  
MRLs, 85  
tolerances, 89
- Cefazolin  
analysis, 158, 188, 194  
chemical structure, 17  
MRLs, 85
- Cefoperazone  
analysis, 138, 158  
chemical structure, 17  
MRLs, 85
- Cefquinome, 14  
analysis, 158  
chemical structure, 17  
MRLs, 85
- Ceftiofur, 1, 14, 103, 194, 230–232  
analysis, 138, 158, 162, 173, 188, 194, 197,  
231–233, 252  
chemical structure, 18, 231  
MRLs, 14, 85  
tolerances, 89
- Cefuroxime  
analysis, 173  
chemical structure, 18
- Cephalosporins, 14, 68–70, 98, 102. *See also*  
 $\beta$ -Lactams  
activity, 6  
analysis, 138, 164, 171, 194, 230. *See also*  
*individual compounds*  
chemical structures, 17, 18  
MRLs, 14, 85  
 $pK_a$ , 17–18
- Cephalothin, 14  
chemical structure, 18
- Chemical Abstract Service Registry Number,  
defined, 2
- Chemical names  
International nonproprietary name (INN), 1  
International Union of Pure and Applied  
Chemistry (IUPAC), 2
- Chemotherapeutic triangle, 4, 53
- Chloramphenicol, 6–8, 30, 31, 52, 66, 73, 74,  
95–97, 112, 153, 227, 234  
analysis, 132, 133, 139, 143, 144, 158, 169,  
170, 172, 176, 177, 179, 180, 187,  
192, 193, 195, 202, 217, 233–235,  
248, 250, 252, 287  
chemical structure, 31, 234  
environmental sources, 119, 120, 235, 236  
minimum required performance limits, 74,  
233, 235, 236
- Chlortetracycline, 45, 49, 68, 79, 80, 120, 244  
analysis, 126, 128, 142, 158, 160, 163, 192,  
193, 245, 246, 249  
chemical structure, 50  
degradation in storage, 126  
MRLs, 52, 87, 244  
tolerances, 89, 244
- Ciprofloxacin, 36, 75–77, 251  
analysis, 141, 190–192, 251  
chemical structure, 42  
MRLs, 86
- Clarithromycin, 21
- Clavulanic acid  
chemical structure, 17  
MRLs, 88
- Clindamycin, 5, 20, 71, 250  
chemical structure, 21
- Cloxacillin, 5, 14  
analysis, 158, 162–164, 173, 188, 189,  
193, 194  
chemical structure, 15  
MRLs, 85, 230  
tolerances, 89
- Cochran's test, 312, 314, 316
- Codex Alimentarius Commission (CAC), 8, 82,  
84, 114, 117, 153, 231, 263, 265, 267,  
268, 295, 298, 333
- Colistin (polymyxin E), 35–36  
analysis, 190  
chemical structure, 37  
MRLs, 36, 88  
pharmacokinetics, 79
- Column efficiency, 195, 196, 198, 199, 246
- Column void volume, 195
- Community Reference Laboratory (CRL), 153,  
156, 176, 179, 181, 227, 239
- Confirmation (of chemical identity), 96, 97,  
125, 154, 160, 163, 187, 200, 204,  
206–212, 227, 230, 233, 240, 243–249,  
251, 270, 275, 278–281, 287, 339, 340
- Confirmatory method (of analysis), 83, 187,  
230, 234, 240, 241, 273, 281, 338  
definition, 270, 280, 339  
performance requirements, 339
- Coverage factor, 296, 302, 305, 308, 312, 317,  
319, 320, 322, 324, 325
- Critical control points (in analytical method),  
274
- Cross-reactivity (in immunoassay), 176, 177,  
179, 180
- Crystal violet (analysis), 180
- Cyadox, 18, 19, 228, 229  
chemical structure, 19
- Dalfopristin, 35, 75  
chemical structure, 40
- Danofloxacin, 36, 44, 75, 76, 103  
analysis, 190–192  
chemical structure, 42  
MRLs, 85  
tolerances, 89
- Dapsone, 52  
analysis, 158, 177, 192, 193  
chemical structure, 46
- Data (uncertainty), 295  
certified reference material (CRM), 299,  
302, 319–324  
in-house (intra-laboratory), 297, 301–312  
inter-laboratory study, 312–317  
proficiency test (PT), 317–319  
quality control (QC), 319–325
- Decision limit ( $CC\alpha$ ), 139, 181, 203, 268,  
284–286, 289, 339  
definition, 181, 289, 339
- Demeclocycline, 45, 244  
analysis, 142, 193, 249  
chemical structure, 50
- Depletion study (residue), 61, 64, 67, 69–71,  
74, 76, 77, 79, 81, 83, 84, 91–93, 95,  
98–101, 127, 128, 251, 266  
explanation of, 114
- Desethyleneciprofloxacin, 76, 77
- Desfuoylceftiofur, 14, 85  
analysis, 188, 194, 230–233  
chemical structure, 231
- Desmocosin, 21  
analysis, 189, 193, 194, 211
- Desoxycarbadox, 18  
analysis, 228–230, 248  
chemical structure, 228
- Detection capability ( $CC\beta$ ), 139, 154, 179, 181,  
203, 268, 284, 285  
definition, 289, 339
- Dicloxacillin  
analysis, 158, 173, 188, 193, 194  
chemical structure, 15  
MRLs, 85, 230
- Difloxacin, 36  
analysis, 141, 190–192, 218  
chemical structure, 42  
MRLs, 86
- Dihydrostreptomycin, 9, 10, 67, 69, 71  
analysis, 158, 177, 188, 193, 197, 198  
chemical structure, 11  
MRLs, 87  
tolerances, 89
- Dilute and shoot, 128–129
- Dimetridazole, 28–30, 73, 95, 96  
analysis, 190, 240–241, 248  
chemical structure, 29, 240
- Dixon's test, 319
- Doxycyclin(e), 5, 49, 52, 68, 79–81, 244  
analysis, 132, 140, 159, 192, 193, 245, 246,  
248  
chemical structure, 50  
MRLs, 245
- Enrofloxacin, 36, 44, 75, 76, 99, 103  
analysis, 72, 134, 141, 169, 180, 190–192,  
218, 251  
chemical structure, 42  
MRLs, 86, 251  
tolerances, 89, 251
- Environment, antibiotics in, 2, 8, 9, 14, 27–29,  
31, 34, 36, 44, 45, 52, 68, 89, 112, 117,  
119, 120, 138, 187, 194, 229, 235, 236,  
244
- 4-Epi-chlortetracycline, chemical structure, 50

- 4-Epi-oxytetracycline, chemical structure, 51  
 4-Epi-tetracycline, chemical structure, 51  
 Erythromycin, 21, 26, 27, 29, 72–74, 96, 120, 307, 308, 311–313  
   analysis, 132, 134, 138, 158, 162, 189, 192–194, 202, 208, 217  
   chemical structure, 22  
   MRLs, 27, 86  
   stability, 132  
   tolerances, 89  
 Estimated dietary intake (EDI), 90, 91  
 Exact mass, 202, 212, 219, 280  
   table, 188–193  
 Experimental design  
   accuracy, 281, 282  
   analyte stability, 271  
   analyte stability during sample storage, 273  
   calibration curve, 276, 277  
     analytical range, 276, 277  
     sensitivity, 277  
   decision limit ( $CC_{\alpha}$ ), 289  
   detection capability ( $CC_{\beta}$ ), 289  
   limit of detection (LOD), 287–289  
   limit of quantification (LOQ), 287–289  
   precision, 283–287  
   recovery, 283–287  
   ruggedness, 273, 274  
   selectivity, 278, 279  
 Export slaughter interval (ESI), 93, 94  
 Exposure (definitions)  
   acute, 113  
   chronic, 113  
   long-term, 113  
   short-term, 113  
 Extraction techniques  
   accelerated solvent extraction (ASE), 130  
   aptamers, 138, 140, 165  
   bipolarity, 129, 145  
   dispersive solid phase extraction (dSPE), 125, 129, 133, 134  
   hot-water ( $H_2O$ ) extraction (HWE), 130  
   immunoaffinity (-based) chromatography (IAC), 96, 125, 138, 139, 144, 216  
   liquid extraction (LE), 125  
   liquid–liquid extraction (LLE), 125, 128, 129, 131, 136, 137, 139, 145, 146, 229, 233, 235  
   liquid–solid extraction (LSE), 125  
   matrix solid phase dispersion (MSPD), 125, 134, 135, 146, 234, 235, 243  
   microextraction by packed sorbent (MEPS), 137, 144–146  
   microwave-assisted extraction (MAE), 125, 142–144  
   molecularly imprinted polymer (MIP), 125, 135, 136, 139, 140, 144, 146, 165, 241, 243, 246  
   pressurized fluid extraction (PFE), 130, 143  
   pressurized hot-solvent extraction (PHSE), 130  
   pressurized liquid extraction (PLE), 125, 130, 131, 145, 235, 243  
   QuEChERS, 129, 130, 133, 145  
   restricted-access materials (RAM), 125, 133, 138, 144–146  
   solid phase extraction (SPE), 125, 128, 129, 131–134, 136–139, 144–146, 176, 194, 197, 229, 230, 232–236, 241, 244, 246, 247, 249–251, 272  
   solid phase microextraction (SPME), 125, 135–137, 144–146  
   stir bar sorptive extraction (SBSE), 125, 137–138, 144–146  
   stirring rod sorptive extraction (SRSE), 137, 138  
   subcritical solvent extraction (SSE), 130  
   supercritical fluid extraction (SFE), 130, 131  
   turbulent-flow chromatography (TFC), 125, 140–141, 144–146  
   ultrafiltration (UF), 128, 132, 142, 145, 244  
   ultrasonically assisted extraction (UAE), 125, 144  
 Extralabel use (of drug), 52, 95, 115, 116  
 Fitness for purpose, 263, 265–270, 274, 276, 280, 281, 289, 327  
   definition, 268  
 Flavophospholipol, 36  
   chemical structure, 41  
 Florfenicol, 1, 30, 31, 73, 74, 87, 93, 103, 119, 120, 127, 134  
   amine, 74, 87, 127, 139, 235, 247, 248, 250  
   analysis, 139, 187, 217, 247–250  
   chemical structure, 31, 234  
   MRLs, 87, 233  
   tolerances, 89  
 Flumequine, 36, 44, 75  
   analysis, 76, 128, 180, 190, 191, 218  
   chemical structure, 42  
   MRLs, 86  
 Fluoroquinolone(s), 4–7, 13, 36, 41, 44, 52, 64, 68, 75–77, 95, 102, 103, 160  
   activity, 6  
   analysis, 132–134, 138, 139, 145, 176, 179, 180, 190–192, 194, 201, 217, 251  
   chemical structures, 42–43  
   pharmacokinetics, 76–77  
    $pK_a$ , 42–43, 194  
   transport (in groundwater), 119  
 Food Analysis Proficiency Assessment Scheme (FAPAS), 272  
 Food Animal Residue Avoidance Databank (FARAD), 94, 95  
 Food basket, 84, 89–91, 116  
 FoodBrand, 96  
 Fragmentation (in mass spectrometry), 200, 206, 207, 209–212, 216, 279, 280  
   pathway(s), 218, 219  
   table, 217  
 Freeze–thaw cycles, 127, 273, 338  
 Furaltone, 194, 236  
   analysis (as AMOZ), 180, 236–238, 248  
   chemical structure, 28, 238  
 Furazolidone, 27, 52, 73, 95, 96, 194, 236  
   analysis (as AOZ), 180, 236–238, 248  
   chemical structure, 28  
   stability, 28  
 Gentamicin, 9, 10, 52, 67, 69, 97, 101, 102, 269  
   analysis, 158, 160, 169, 170, 176, 180, 188, 197, 198, 217, 249  
   chemical structure, 11, 247  
   degradation in storage, 126  
   MRLs, 87  
   tolerances, 89  
 Gram negative, definition of, 3  
 Gram positive, definition of, 3  
 Gram stain, 3, 154  
 Grubb's test, 313–316, 319  
 Henderson–Hasselbalch equation, 2, 5  
 Hetacillin, 174  
   analysis, 173  
 HILIC, 188, 191, 196–198, 246  
 Homogenization (of sample), 127, 128, 144, 303, 304  
 Horwitz formula (also equation or model), 297, 312–314, 317, 318, 342  
 Identification (of compound), 1, 61, 70, 83, 96, 114, 125, 132, 163, 164, 187, 200, 205, 207–211, 216, 237, 239, 247, 253, 274, 279, 288, 333, 340  
 Identification point (IP) in mass spectrometry, 96, 154, 208, 211–212, 230, 249, 280–281, 339  
   table, 208  
 Injection site, 27, 62, 70, 73, 74, 80, 95, 96, 98–101, 126  
 Ionization (in mass spectrometry), 2, 138, 142, 195, 196, 200–203, 205, 214, 216, 233, 236, 280  
   table, 188–193  
 Ion mobility spectrometry, 214  
 Ionophores, 31–35, 74, 75, 101  
   analysis, 129, 132, 145, 180, 202. *See also individual compounds*  
   chemical structures, 32–33  
   MRLs, 88  
   pharmacokinetics, 75  
    $pK_a$ , 32, 33  
   stability, 35  
 Ion-pairing agent (IPA), 196, 197  
 Ion ratio, 208  
   table (relative ion intensity), 208  
 Iprnidazole, 28–30, 95  
   analysis, 240–241, 248  
   chemical structure, 29, 240  
 Joint FAO/WHO Expert Committee on Food Additives (JECFA)  
   evaluations, 9, 10, 14, 19, 20, 27, 28, 30, 31, 34, 36, 44, 45, 52, 82, 90, 91, 112, 153, 227, 228, 230, 233, 235, 239, 242, 244, 283  
   role, 113, 117, 265–266  
 Joint FAO/WHO Meeting on Pesticide Residues (JMPR), 113, 117  
 Kanamycin, 9, 67, 69, 102  
   analysis, 158, 188, 197, 198

- Kanamycin (*Continued*)  
 chemical structure, 11  
 MRLs, 87
- Kitasamycin (leucomycin A1), chemical structure, 23
- Lasalocid, 31, 32, 34, 74, 75  
 analysis, 189, 190  
 chemical structure, 32  
 MRLs, 88
- Leucomalachite green, analysis, 180, 219
- Lincomycin, 20, 71, 72, 119, 120  
 analysis, 158, 189, 192, 196, 197, 217, 250  
 chemical structure, 21  
 MRLs, 20, 87, 195, 250  
 reverse metabolism (in analysis), 250  
 tolerances, 89
- Lincosamides, 20, 65, 68, 71, 72  
 activity, 6, 7  
 analysis, 129, 131, 133, 145, 172, 189, 192, 197, 217, 250. *See also individual compounds*  
 chemical structures, 21  
 distribution in tissues, 72  
 MRLs, 20, 87, 195, 250  
 pharmacokinetics, 72  
 $pK_a$ , 21  
 reverse metabolism (in analysis), 250  
 tolerances, 89
- Macrolide(s)  
 analysis, 128, 129, 131–133, 136, 138, 189, 192–194, 199, 200, 206, 211, 217, 227, 297, 306–308, 311, 313, 317. *See also individual compounds*  
 chemical structures, 22–25  
 MRLs, 86  
 pharmacokinetics, 72–73  
 $pK_a$ , 194  
 stability, 132  
 tolerances, 89
- Maduramicin, 31, 32, 74  
 analysis, 189, 190  
 chemical structure, 32
- Malachite green, 180
- MALDI, 200, 201, 216
- Mandel's  $h$  statistic(s), 312, 314, 315
- Mandel's  $k$  statistic(s), 312, 314–316
- Marbofloxacin, 36, 75, 76  
 analysis, 191, 193  
 chemical structure, 42
- Marker residue, 61, 64, 71, 74, 83–91, 93, 100, 114–117, 127, 153, 194, 227–231, 233, 236, 237, 239, 240, 242, 244, 245, 247, 250–253, 266, 269, 317
- Mass accuracy (also mass error), 208, 211, 214, 215
- Mass spectrometer(s), 205–214  
 ion trap, 205, 206, 208, 209, 213  
 linear ion trap (LIT), 205, 209–211  
 Orbitrap, 205, 209, 212–214, 216  
 table, 188–193  
 time-of-flight (TOF), 205, 210–212, 214, 216
- triple-quadrupole (QqQ), 205–208, 210
- Mass spectrometry, fragmentation pathways, 218
- Matrix effects, 201–204, 306, 312  
 calibration curve, 202, 203  
 experimental determination of, 202, 286–287
- Matrix matched, 286–287
- Maximum residue limits (MRLs), 1, 61  
 derivation of, 114, 116–117  
 information sources (databases), 84, 118  
 table (EU), 85–88
- McIlvaine buffer, 246
- Mecillinam, chemical structure, 15
- Metaphylaxis, 9, 66–67
- Methacycline, 244  
 chemical structure, 50
- Methicillin, 14  
 chemical structure, 16
- Method development, 271–272
- Method performance terms  
 accuracy, 281, 282  
 analytical range, 275–277  
 bias, 281, 282, 297, 299–302, 306, 308, 312, 317–319, 341, 343  
 calibration curve (requirements), 202, 203, 269, 275–277, 284, 286, 287  
 precision, 283  
 coefficient of variation, 283  
 intermediate precision, 283  
 relative standard deviation, 283  
 repeatability, 283  
 reproducibility, 283  
 recovery, 282, 283  
 selectivity, 277–279  
 in mass spectrometry, 279–281  
 sensitivity, 277  
 trueness, 281, 282  
 true value, 282
- Metronidazole, 7, 28–30, 73, 90, 95, 96  
 analysis, 190, 240, 241, 248  
 chemical structure, 29, 240
- Microbe, 2, 5, 7  
 definition of, 3
- Microorganism, definition of, 3
- Minimum bactericidal concentration (MBC), 5–7, 53, 64
- Minimum inhibitory concentration (MIC), 5, 7, 36, 53, 64
- Minimum required performance limit (MRPL), 73, 153, 338
- Minocycline, 80, 244  
 chemical structure, 50
- Mirincamycin, 250
- MLSB resistance, 20
- Mobile phase, 195–199, 201  
 table, 188–193
- Molecular formula(s), 211, 219  
 table, 188–193
- Monensin, 31, 32, 34, 74, 75, 95  
 analysis, 132, 189, 190, 192, 217  
 chemical structure, 32  
 MRLs, 88
- Multi-class, 128, 131–133, 145, 187, 192, 194
- Multiple-reaction monitoring (MRM), 202, 205–211
- Multiple-reaction monitoring (MRM) transitions, *see* Transitions
- Multi-residue (methods), 96, 128, 139, 160, 164, 169, 170, 176, 179, 180, 199, 216, 227, 247, 251, 267, 268, 285
- Nafcillin  
 analysis, 142, 188, 193, 194  
 chemical structure, 16  
 MRLs, 85
- Nalidixic acid, 36, 75  
 analysis, 190, 191  
 chemical structure, 43, 218
- Narasin, 31, 32, 34, 74, 75  
 analysis, 189, 217  
 chemical structure, 33
- Neomycin, 9, 10  
 analysis, 162, 180, 188, 193, 197, 198, 249  
 chemical structure, 12, 247  
 MRLs, 87  
 tolerances, 89
- Neospiramycin  
 analysis, 189, 202  
 chemical structure, 23  
 MRLs, 86
- Nephrotoxicity, 9
- Nested design, 305, 306
- Nifuroxazide, 27  
 chemical structure, 28
- Nitrofurantoin(s), 7, 27, 28, 52, 73, 74, 94, 96, 102, 127, 194, 227, 236  
 analysis, 236–239, 248, 252, 253. *See also individual compounds*  
 chemical structures, 28  
 Community Reference Laboratory (CRL) recommendation, 239  
 metabolism, 237–239  
 minimum required performance limits, 74, 96, 236  
 $pK_a$ , 28
- Nitrofurantoin, 27, 194  
 analysis (as AHD), 180, 236–238, 248  
 chemical structure, 28
- Nitrofurazone, 27, 52, 95, 194, 236  
 analysis (as SEM), 180, 236–239, 248  
 chemical structure, 28
- Nitroimidazoles, 28–30, 73, 239  
 analysis, 129, 131, 240, 241, 248, 253. *See also individual compounds*  
 chemical structures, 29, 240  
 metabolism, 240, 241  
 MRLs, 239  
 $pK_a$ , 29
- No observable adverse effect level (NOAEL), explanation of, 61, 113
- No observable effect level (NOEL), explanation of, 61, 113
- Norfloxacin  
 analysis, 180, 191  
 chemical structure, 43
- Novobiocin, 35, 36  
 analysis, 172

- chemical structure, 38  
MRLs, 88
- Olaquinox, 18–20, 52, 71, 227  
analysis, 180  
chemical structure, 19  
MRLs, 71  
stability, 19
- Oleandomycin, 21, 72  
analysis, 189, 193, 206, 207  
chemical structure, 23
- Orbifloxacin, 36  
chemical structure, 43
- Ormetoprim, 45, 77  
chemical structure, 49  
MRLs, 242
- Ornidazole  
analysis, 240, 241, 248  
chemical structure, 240
- Oxacillin  
analysis, 188, 189, 193, 194  
chemical structure, 16  
MRLs, 85, 230
- Oxociprofloxacin, 76
- Oxolinic acid, 36, 44, 75  
analysis, 190, 191  
chemical structure, 43, 218
- Oxytetracycline, 45, 49, 52, 79–81, 244  
analysis, 128, 141, 142, 162, 192, 193, 217, 244–246, 249  
chemical structure, 51, 219  
MRLs, 52, 87, 244  
tolerances, 89, 244
- Paromomycin  
analysis, 188  
chemical structure, 12  
MRLs, 87
- Penethamate  
analysis, 193  
chemical structure, 16  
MRLs, 85
- Penicillinase, 126
- Penicillin(s), 194  
analysis, 128, 132, 155, 188, 189, 193. *See also individual compounds*  
benzathine benzylpenicillin salts, 70, 99, 100  
chemical structures, 15, 16  
MRLs, 85  
pharmacokinetics, 69–71  
 $pK_a$ , 15, 16  
procaine penicillin salts, 70, 99
- Peptidoglycan, 3, 6, 13, 34–36, 171
- Pharmacodynamics, 4–7, 64, 66
- Pharmacokinetics (PK)  
definition of, 1, 4, 61  
flip-flop, 62, 65, 70, 72, 74, 76, 78, 80, 98, 99, 101
- Pharmacokinetic parameters  
area under curve (AUC), 62–66  
bioavailability (F%), 62–66  
clearance (Cl), 62–66  
maximum plasma concentration ( $C_{max}$ ), 62, 63
- terminal half-life ( $T_{1/2}$ ), 62, 63, 65  
time of maximum concentration ( $T_{max}$ ), 62, 63  
very late terminal phase, 62, 63  
volume of distribution in steady-state condition ( $V_{ss}$ ), 62, 66  
volume of distribution, terminal phase ( $V_{area}$ ), 62, 65, 66
- Phenicol, 30, 31  
activity, 6, 7  
analysis, 132, 176, 192, 193, 233–235, 248. *See also individual compounds*  
chemical structure, 31  
metabolism, 234  
pharmacokinetics, 74
- Phenoxymethyl penicillin (Penicillin V), 14  
chemical structure, 16  
MRLs, 85
- Phthalylsulfathiazole, 45  
chemical structure, 46
- Pirlimycin, 174  
analysis, 250  
chemical structure, 21  
MRLs, 20, 87, 153, 250  
reverse metabolism, 250  
tolerance, 89
- $pK_a$ , definition of, 2
- Pleuromutilin(s), 6, 7, 21, 22, 71  
analysis, *see individual compounds*  
chemical structures, 26  
MRLs, 87  
pharmacokinetics, 72  
 $pK_a$ , 26
- Polymixin(s)  
analysis, 190. *See also individual compounds*  
chemical structure, 38  
pharmacokinetics, 79
- Polymyxin B, 35, 36, 79  
analysis, 190  
chemical structure, 38,
- Polypeptide(s), 35, 36  
analysis, 190, 202. *See also individual compounds*  
chemical structures, 37, 38  
MRLs, 36  
pharmacokinetics, 75  
 $pK_a$ , 38
- Post-antibiotic effect (PAE), 7
- Post-antibiotic leukocyte enhancement (PALE), 7
- Pristinomycin, 35
- Proficiency testing, 341, 342
- Prontosil, 44
- Prophylaxis, 9, 26, 61, 66, 72, 80
- Purity of analyte, 270, 271
- Quality, definition of, 327
- Quality assurance, definition, 327, 328
- Quality control  
control charts, 265, 342–344  
definition, 328  
elements of, 336–338
- Quality management  
audits, 331  
conformity assessment, definition, 331  
definition, 329  
documentation, 330, 331  
process management, 330  
technical elements, 331
- Quality manual, 330
- Quality system  
accreditation, definition, 332  
certification, definition, 332  
definition, 328  
international requirements (CAC, EU), 332, 333  
international standards, 328  
ISO/IEC 17025: 2005 requirements, 334, 335  
OECD GLP requirements, 336  
objective, 328  
requirements, 329  
review, 331  
role of analyst, 333
- Quantitative method (definition), 270
- Quindoxin, 18  
chemical structure, 19
- Quinolone(s) (includes fluoroquinolones), 1, 36, 44, 75  
activity, 7  
analysis, 128, 129, 131, 132, 134, 135, 141, 160, 190–192, 199, 200, 217. *See also individual compounds*  
chemical structures, 42, 43  
MRLs, 86, 251  
pharmacokinetics, 76, 77, 251  
tolerances, 89, 251  
 $pK_a$ , 42, 43
- Quinoxalines, 18–20, 227–229  
analysis, 229, 230, 248, 252. *See also individual compounds*  
chemical structures, 19, 228  
metabolism, 18, 71, 227, 228  
pharmacokinetics, 71
- Quinupristin, 35  
chemical structure, 40
- Random error, 297, 317
- Rapid tests: *See also* Test kits  
immunoassay(s), 164–171  
basic principles, 164, 165  
dipstick (*see* LFIA), 165  
ELISA, 165, 178–181  
immunochromatographic test strip (*see* LFIA), 165  
lateral flow device (LFD), 165  
lateral flow immunoassay (LFIA), 165–169  
radioimmunoassay, 165, 170  
surface plasmon resonance, 165, 174–178  
microbial inhibition assays, 154–164  
Calf Antibiotic Screen Test (CAST), 160  
Fast Antibiotic Screen Test (FAST), 160  
Four-Plate Test (FPT), 156  
New Dutch Kidney Test (NDKT), 156

- Rapid tests (*Continued*)  
 screening test for antibiotic residues (STAR), 156  
 seven-plate agar diffusion assay (USDA/FSIS), 156  
 swab test on premises (STOP), 97, 160  
 sensitivity, 160, 161
- Recommended concentration (RC), 153, 176, 179, 181, 182
- Reference point for action (RPA), 153, 338
- Regulatory limit (RL), 153, 181, 182, 296
- Residue control program(s), categories of, 96–98
- Residues (antibiotic)  
 bound, 81, 96, 114, 127  
 conjugated forms, 127  
 degradation (causes of), 127  
 in crops, 119, 120  
 in groundwater, 119  
 in landfill sites, 119
- Resolution (LC), 195, 196, 198–200  
 definition of, 195
- Resolution (MS), 205, 206, 208–211, 213, 214, 216  
 definition of, 211
- Retention factor, 197, 198  
 definition of, 195
- Risk assessment, 84, 88–91
- Risk communication, 94
- Risk management, 91–94
- Rolitetraacycline, 244
- Ronidazole, 28  
 analysis, 190, 240, 241, 248  
 chemical structure, 29, 240
- Roxithromycin  
 analysis, 138, 189, 193, 202  
 chemical structure, 24
- Ruggedness (robustness), 181, 273, 274
- Ruggedness test, 303–305  
 definition, 273
- Salinomycin, 31, 32, 34, 52, 74, 75, 95  
 analysis, 141, 144, 189, 190, 217  
 chemical structure, 33
- Sample disruption, 128
- Sarafloxacin, 36, 75  
 chemical structure, 43
- Screening method  
 definition, 270  
 performance criteria, 181  
 performance requirements, 338  
 screening target concentration (STC), 181, 182
- Semduramicin, 31, 32, 74  
 analysis, 189  
 chemical structure, 33
- Significant figures, 289
- Spectinomycin, 9, 69  
 analysis, 188, 197, 198  
 chemical structure, 13  
 MRLs, 10  
 tolerances, 89
- Spiramycin, 21, 27  
 analysis, 141, 142, 180, 189, 193, 202  
 chemical structure, 24  
 MRLs, 27, 86
- Stability  
 analyte, 3, 126, 127, 194, 199, 270, 271  
 during processing, 3, 126–128, 272  
 during storage, 3, 126–128, 272, 273  
 product (formulated), 3, 8
- Streptomycin, 8–10  
 analysis, 176, 177, 180, 188, 192, 193, 197, 198  
 chemical structure, 12  
 MRLs, 88  
 tolerances, 89
- Sulfabenzamide, 242  
 analysis, 192, 193, 248  
 chemical structure, 46
- Sulfacetamide, 242  
 analysis, 248  
 chemical structure, 46
- Sulfachloropyridazine  
 analysis, 191, 193, 248  
 chemical structure, 46
- Sulfadiazine, 20, 44, 45, 78, 242  
 analysis, 177, 180, 191–193, 248  
 chemical structure, 46, 218
- Sulfadimethoxine, 45, 52, 78, 242  
 analysis, 191–193, 248  
 chemical structure, 46, 218
- Sulfadoxin(e), 77, 242  
 analysis, 191–193, 248  
 chemical structure, 47
- Sulfaethoxypyridazine, 242  
 analysis, 248
- Sulfafurazole (sulfisoxazole)  
 analysis, 191, 192, 242, 248  
 chemical structure, 49
- Sulfaguanidine, 77, 78, 242  
 analysis, 248  
 chemical structure, 47
- Sulfamerazine, 78, 242  
 analysis, 191, 193, 248  
 chemical structure, 47, 218\*
- Sulfameter: *see* Sulfametyoxydiazine
- Sulfamethazine (sulfadimidine), 44, 45, 78, 242, 298, 299  
 analysis, 141, 177, 180, 191–193, 217, 248  
 chemical structure, 47, 218  
 degradation in storage, 126  
 MRLs, 242
- Sulfamethizole  
 analysis, 191, 242, 248  
 chemical structure, 47
- Sulfamethoxazole, 44, 120, 210  
 analysis, 158, 177, 180, 191–193, 242, 248  
 chemical structure, 47
- Sulfamethoxydiazine (sulfameter)  
 analysis, 191–193, 242, 248  
 chemical structure, 48
- Sulfamethoxypyridazine  
 analysis, 191–193, 242, 248  
 chemical structure, 47
- Sulfamonomethoxine  
 analysis, 191, 242, 248  
 chemical structure, 48
- Sulfamoxole  
 analysis, 192, 193, 242, 248  
 chemical structure, 48
- Sulphanilamide, 44, 77, 242  
 analysis, 193, 248  
 chemical structure, 48
- Sulfantran, 242  
 analysis, 248  
 tolerance(s), 242
- Sulfaphenazole  
 analysis, 242, 248  
 chemical structure, 48
- Sulfapyridine, 242  
 analysis, 191–193, 248  
 chemical structure, 48
- Sulfaquinoxaline, 78, 242  
 analysis, 180, 191–193, 248  
 chemical structure, 48, 218
- Sulfathiazole, 44, 96, 242  
 analysis, 159, 191–193, 248  
 chemical structure, 49
- Sulfisomidine  
 analysis, 192, 193, 242, 248  
 chemical structure, 49
- Sulfisoxazole: *see* Sulfafurazole
- Sulfonamide(s), 44, 45, 77, 198–200, 202, 206, 216, 241, 242  
 analysis, 128, 129, 131, 132, 134, 136, 137, 139, 142, 144, 163, 164, 169, 176, 177, 179, 180, 191–193, 210, 217, 243, 244, 253. *See also individual compounds*  
 chemical structure, 46–49  
 metabolism, 78, 242, 243  
 MRLs, 85, 242  
 pharmacokinetics, 77–79  
 $pK_a$ , 46–49, 194  
 tolerances, 89, 242
- Sulfonamide, potentiated, 7, 44, 45, 102
- Swann (report), 8
- Systematic error, 282, 297
- Target tissue, 61, 63, 74, 84–88, 93, 99, 114, 117, 269
- Teicoplanin, 35, 75  
 chemical structure, 39
- Temocillin, 14  
 chemical structure, 16
- Ternidazole  
 analysis, 240, 241, 248  
 chemical structure, 240
- Test kits (commercial rapid tests)  
 BR-Test AS Brilliant, 157  
 Bacillus stearothermophilis disk assay (BsDA), 157, 159  
 Betastar, 168  
 $\beta$ -STAR 1+1, 98  
 Charm II, 170, 172  
 Charm Blue Yellow II, 157, 159  
 Charm Cowside II, 157  
 Charm kidney inhibition swab (KIS test), 159, 160  
 Charm II Tablet Competitive Beta-lactam, 98  
 Charm MRL-3, 98

- Charm SL-Beta-lactam, 98  
 DelvoTest, 156, 157, 159  
 DelvoTest SP, 157  
 DelvoTest SP-NT, 157  
 DelvoTest P5 Pack Beta-lactam, 98  
 Delvo-X-PRESS, 172, 173  
 Eclipse, 157  
 Explorer, 159  
 IDEXX SNAP Beta-lactam, 98  
 Innovation Copan Milk Test (CMT), 157  
 Penzyme Milk Test, 171, 173  
 PremiTest, 159  
 QFlex, 175  
 rapid one-step assay (ROSA), 168, 169  
 SNAP, 169, 173  
 sulfasensor, 168, 169  
 tetrasensor, 168–170  
 trisensor, 168, 169  
 twinsensor, 168, 169
- tetracycline (compound), 8, 49, 52, 79, 242  
 analysis, 140, 142, 192, 193, 244–246, 248  
 chemical structure, 51  
 MRLs, 52, 87, 244  
 tolerances, 244
- tetracyclines (group), 45, 244  
 analysis, 128, 129, 131, 132, 133, 142, 163–164, 169, 170, 180, 192, 193, 217, 244–246, 249, 253. *See also individual compounds*  
 epimerization, 128, 131, 244–245  
 chemical structures, 50–51  
 MRLs, 52, 87, 244  
 pharmacokinetics, 79–81  
 $pK_a$ , 194  
 stability, 246  
 tolerances, 89, 244
- Thiamphenicol, 30, 74, 187, 234  
 analysis, 235  
 chemical structure, 31, 234
- Threshold dose, 30, 88, 113
- Tiamulin, 1, 21, 26, 34, 72, 252  
 chemical structure, 26  
 MRLs, 87, 251  
 tolerances, 89
- Ticarcillin, chemical structure, 16
- Tigecycline, 49, 81, 244
- Tilmicosin, 1, 21, 72, 73  
 analysis, 132, 138, 180, 189, 192, 193, 202  
 chemical structure, 24  
 MRLs, 27, 86  
 tolerances, 89
- Tinidazole, 28  
 analysis, 248  
 chemical structure, 29, 240
- Theoretical maximum daily intake (TMDI), 89–91, 116
- Tobramycin, 67  
 analysis, 188, 249  
 chemical structure, 13, 247
- Tolerances (USA), 61  
 derivation of, 114–116  
 information sources (databases), 118  
 table, 89
- Top-down, 287, 297, 319
- Toxicity studies, 82, 83
- Transition(s) (also multiple reaction monitoring transition), 202, 205–208, 210, 211, 229, 230, 235–237, 240, 243, 245, 249  
 table, 188–193, 248, 249
- Trimethoprim, 6, 7, 44, 45  
 analysis, 131, 133, 136  
 chemical structure, 49  
 MRLs, 242
- Tulathromycin, 1, 21  
 chemical structure, 25  
 MRLs, 86, 227, 251
- Tylosin, 1, 2, 21, 26, 27, 52, 120  
 analysis, 138, 159, 163, 177, 180, 189, 192, 193, 202, 211, 212  
 chemical structure, 25  
 MRLs, 27, 86  
 stability, 194, 211, 212  
 tolerances, 89
- Tylvalosin (acetylisovalerylytylosin), 72, 73  
 chemical structure, 25  
 MRLs, 87
- UPLC (UHPLC), 128, 129, 132, 144, 187, 189, 198–200, 202, 211, 213, 214, 219, 220, 235, 236, 241, 243, 245
- Uncertainty  
 combined, 6, 298, 302, 305, 312, 320, 322, 324, 325  
 expanded, 296, 297, 302, 305, 308, 312, 317, 319, 323–325
- Validation (of analytical method), 263, 274  
 criteria approach, 266, 267, 334  
 definition, 265  
 experimental design, 275  
 management of, 274, 275  
 measurement uncertainty (determination of), 287  
 method performance characteristics, 268  
 method scope, 274  
 single laboratory validation (SLV), 266, 267  
 sources of guidance  
 AOAC International, 264  
 Codex Alimentarius Commission, 265, 268  
 Eurachem, 265  
 European Commission, 266, 268  
 ICCVAM, 265  
 ICH, 265, 268  
 ISO, 264, 265, 268  
 IUPAC, 263, 264, 267, 268  
 JCGM, 268  
 JECFA, 265, 266  
 NATA, 268  
 USFDA, 266, 268  
 VICH, 82, 113, 117, 265, 268
- Valnemulin, 21  
 chemical structure, 26  
 MRLs, 87
- Vancomycin, 3, 7, 35, 75  
 chemical structure, 40
- van Deemter equation (also plot), 198, 199
- Virginiamycin, 35, 36, 41, 52  
 analysis, 180, 190
- Volume of distribution, 9, 62, 63, 65, 66, 69, 72–74, 76, 79, 81, 95
- Withholding (withdrawal) time, 63, 91, 93, 114, 115, 117
- Xenobiotic, 93